Kyowa Hakko Kirin Co Ltd

Type: Company

Name: Kyowa Hakko Kirin Co Ltd

Nationality: Japan

Web Address: http://www.kyowa-kirin.co.jp/english/

Fact Sheet: Fact Sheet for Kyowa Hakko Kirin Co Ltd

First reported May 16 2013 - Updated May 17 2013 - 1 reports

Kyowa Hakko Kirin Co Ltd

Citicoline Supplementation May Significantly Slow Glaucoma Progression

Citicoline is well known as a powerful brain health nutrient, and now is being counted as a supplement that may significantly slow the progression of visual acuity loss due to glaucoma. Researchers at the Sao Paolo Hospital Eye Clinic at the University ... [Published Individual.com - May 16 2013]

Entities: Citicoline, Glaucoma, Kyowa Hakko Kirin Co Ltd, free Radical

First reported May 16 2013 - Updated May 16 2013 - 1 reports

SupplySide MarketPlace Review: New Data on Glutathione Blood Levels

Kyowa Hakko USA (New York City) discussed the results of its latest company-funded study on its Setria glutathione antioxidant ingredient. The study represents the largest, most significant human clinical blood study done on Setria to date, demonstrating ... [Published Nutritional Outlook - May 16 2013]

Entities: glutathione, Marketplace, Antioxidants, Kyowa Hakko Kirin Co Ltd, immune function

First reported May 13 2013 - Updated May 13 2013 - 1 reports

DKSH inks pact with Kyowa Hakko Kirin to provide regulatory services for new biotech drugs

DKSH Business Unit Healthcare, a leading partner for healthcare companies seeking to grow their business in Asia, has signed an agreement with Kyowa Hakko Kirin (Thailand) Co. Ltd., to provide regulatory consulting and product registration services for ... [Published PharmaBiz - May 13 2013]

Entities: Dksh Holding Ltd, Kyowa Hakko Kirin Co Ltd, Thailand, Biotechnology, Drugs

First reported May 10 2013 - Updated May 10 2013 - 1 reports

Shionogi

Bacterial Partnering Terms and Agreements - 2013 Report Features Over 1,000 Links to Online Copies of Actual Bacterial Deals

(M2 PRESSWIRE via COMTEX News Network) -- Research and Markets (http://www.researchandmarkets.com/research/2ng6vc/bacterial) has announced the addition of the "Bacterial Partnering Terms and Agreements" report to their offering. The Bacterial Partnering ... [Published PredictWallStreet - May 10 2013]

Entities: Aspen Pharmacare Holdings Ltd, Shionogi, Menarini Group

First reported May 10 2013 - Updated May 10 2013 - 1 reports

Kyowa Hakko Kirin Co., Ltd. (4151) - Financial and Strategic SWOT Analysis Review - new company profile report

Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakoo), formerly known as Kyowa Hakko Kogyo Co., Ltd., is a biotechnology company. It is focused on the discovery, development, production and commercialization of pharmaceuticals and biotechnology products. The company's ... [Published TransWorldNews - May 10 2013]

Entities: Kyowa Hakko Kirin Co Ltd, SWOT Analysis, Istradefylline, Romiplostim, Antibody

First reported May 08 2013 - Updated May 09 2013 - 1 reports

Daiichi Sankyo Co Ltd

ARQULE INC - 10-Q - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

We are a clinical-stage biotechnology company engaged in the research and development of innovative cancer therapeutics. Our mission is to produce novel drugs with differentiated mechanisms of action that will extend the lives of our patients. These drugs ... [Published Pharmacy Choice - May 08 2013]

Entities: Tivantinib, Daiichi Sankyo Co Ltd, Kyowa Hakko Kirin Co Ltd, Phase III

First reported May 08 2013 - Updated May 08 2013 - 1 reports

Dksh Holding Ltd

DKSH Partners with Thailand Co.

Related Searches: Regulatory Affairs • Collaborations & Alliances • • Regulatory Affairs •Related Breaking NewsDKSH Business Unit Healthcare, a partner for healthcare companies looking to grow their business in Asia, signed an agreement with Kyowa Hakko ... [Published Contract Pharma - May 08 2013]

Entities: Dksh Holding Ltd, Thailand, Kyowa Hakko Kirin Co Ltd, Regulatory Affairs, Health Care

First reported Apr 26 2013 - Updated Apr 26 2013 - 1 reports

Google Ventures is betting its money on these 8 healthcare and life sci companies

Google Ventures has been backing startups through its venture capital fund since 2009 and offers a pretty diverse range of services to entrepreneurs. Here’s a look at the eight healthcare and life science businesses among its portfolio companies spanning ... [Published MedCity News - Apr 26 2013]

Entities: Google Ventures, Health Care, Startup, Oncology, Drugs

First reported Apr 23 2013 - Updated Apr 23 2013 - 1 reports

Girindus (FRK)

The Kyowa Hakko Kirin Group is an R&D-based life sciences company with special strengths inbiotechnology. The Kyowa Hakko Kirin Group companies strive ... ... [Published Euroland - Apr 23 2013]

Entities: Girindus AG, Kyowa Hakko Kirin Co Ltd, Life Science

First reported Apr 22 2013 - Updated Apr 23 2013 - 1 reports

Competitor Analysis: Thrombopoiesis Stimulating Agents (TPO and IL-11)

he present Competitive Intelligence Report Thrombopoiesis Stimulating Agents (TPO and IL-11) as of April 2013 provides information on thrombopoiesis stimulating agents targeting the thrombopoietin, interleukin-11 or other receptors on the market and in ... [Published Research and Markets - Apr 22 2013]

Entities: IL-11, Research & Development, interleukin-11, Uni-Bio Science Group Ltd

First reported Apr 21 2013 - Updated Apr 21 2013 - 1 reports

ProStrakan has eye on future as firm returns to growth

IN THE reception area at the Galashiels offices of drugs developer ProStrakan is a doll's head flanked by UK and Japanese flags.Visitors may notice only one eye of the traditional Daruma doll, a symbol of good luck, has been painted. It is a custom in ... [Published NewsRT.co.uk - Apr 21 2013]

Entities: Prostrakan Group plc, Kyowa Hakko Kirin Co Ltd, Acquisition, Japan

First reported Apr 10 2013 - Updated Apr 10 2013 - 4 reports

Research and Markets: Metabolic Partnering Yearbook 2013: Understand partnering deals and agreements Business Wire

DUBLIN--(BUSINESS WIRE)-- Research and Markets has announced the addition of the "Metabolic Partnering Yearbook 2013" report to their offering. The Metabolic Partnering Yearbook 2013 report series provides comprehensive understanding and unprecedented ... [Published Yahoo! Finance - Apr 10 2013]

Entities: Aspen Pharmacare Holdings Ltd, Menarini Group, Dainippon Sumitomo Pharma Co Ltd, Endo Pharmaceuticals Holdings Incorporated, Shionogi

Quotes

...Its discovery has been heralded as "a major scientific breakthrough that happens once every decade or so" and represents one of the most promising and rapidly advancing frontiers in biology and drug discovery today which was awarded the 2006 Nobel Prize for...

Alnylam Presents Key Pre-Clinical Proof-of-Concept Data for ALN-AS1, an RNAi Therapeutic Targetin ... [Published Business Wire - May 17 2013]

In-demand study "N-Butanol Market by Applications (Butyl Acrylate, Butyl Acetate, Glycol Ethers, and Others) & Geography-Global Trends & Forecasts to 2018" created by MarketsandMarkets examines the global n-butanol market, categorising it on the basis of applications and geography; forecasting revenues and...

Worldwide N-Butanol Market Examined by MarketsandMarkets in . . . [Published Equities.com - May 15 2013]

"Abstral is the latest and best-in-class drug for this indication" president and CEO Mark Ahn says in an interview with BioTuesdays.com, noting that the company is on track for a fourth quarter launch

Galena Targets Cancer Pain Market [Published Seeking Alpha - May 15 2013]

"The official opening of this warehouse reinforces CEVA’s leading presence in the Italian market and commitment to providing unique solutions for the healthcare industry. We also continue to implement our strategy of creating specialized multi-customer logistics hubs that deliver true value and considerable economies of scale,” said Giuseppe Chiellino, managing director, Italy."

More cold-chain logistics resources: 'City of Pharma' in Italy, and upgraded facilities in southe ... [Published Pharmaceutical Commerce - May 15 2013]

More Content

sort by: Date \| Relevance
Alnylam Presents Key Pre-Clinical Proof-of-Conc... [Published Business Wire - May 17 2013]
NPS Pharmaceuticals CEO Dr. Francois Nader Reco... [Published Citybizlist - May 16 2013]
Citicoline Supplementation May Significantly Sl... [Published Individual.com - May 16 2013]
SupplySide MarketPlace Review: New Data on Glut... [Published Nutritional Outlook - May 16 2013]
Worldwide N-Butanol Market Examined by Marketsa... [Published Equities.com - May 15 2013]
Galena Targets Cancer Pain Market [Published Seeking Alpha - May 15 2013]
More cold-chain logistics resources: 'City of P... [Published Pharmaceutical Commerce - May 15 2013]
AVEO, Has Remained On Naked Short Lists 13 Cons... [Published Individual.com - May 14 2013]
NPS Pharmaceuticals Posts First Quarter 2013 Fi... [Published Individual.com - May 14 2013]
Chief Executive's blog: Biotechnology in Korea ... [Published BBSRC - May 13 2013]
Biotechnology in Korea and Japan [Published Professor Douglas Kell's blog - May 13 2013]
DKSH inks pact with Kyowa Hakko Kirin to provid... [Published PharmaBiz - May 13 2013]
Bacterial Partnering Terms and Agreements - 201... [Published PredictWallStreet - May 10 2013]
Kyowa Hakko Kirin Co., Ltd. (4151) - Financial ... [Published TransWorldNews - May 10 2013]
Viral Partnering Terms and Agreements - 2013 Re... [Published Individual.com - May 09 2013]
NPS Pharmaceuticals Reports First Quarter 2013 ... [Published Freshnews.com - May 09 2013]
NPS Pharmaceuticals Reports First Quarter 2013 ... [Published EON - May 09 2013]
NPS Pharmaceuticals Reports First Quarter 2013 ... [Published Yahoo! Finance - May 09 2013]
ArQule Management Discusses Q1 2013 Results - E... [Published Seeking Alpha - May 08 2013]
ARQULE INC - 10-Q - MANAGEMENT'S DISCUSSION AND... [Published Pharmacy Choice - May 08 2013]
Alnylam to Webcast Presentation at 2013 Bank of... [Published Yahoo! Finance - May 08 2013]
DKSH Partners with Thailand Co. [Published Contract Pharma - May 08 2013]
Alnylam to Webcast Presentation at 2013 Bank of... [Published Business Wire - May 08 2013]
NPS Pharmaceuticals Among 100 Best Places to Wo... [Published Equities.com - May 08 2013]
Gastrointestinal Partnering Terms and Agreement... [Published Individual.com - May 08 2013]
Recently released market study: T-Cell Lymphoma... [Published Live-PR.com - May 05 2013]
SIRO, APA, TOO, ARQL Expected To Be Down Before... [Published Individual.com - May 02 2013]
NPS PHARMACEUTICALS, INC.: NPS Pharmaceuticals ... [Published 4 Traders - May 01 2013]
NPS Pharmaceuticals to Report First Quarter 201... [Published BioPortfolio - May 01 2013]
MFLX, NPSP, DNB, BEBE, CNQ, ED Expected To Be D... [Published Individual.com - May 01 2013]

sort by: Date \| Relevance
Biotechnology in Korea and Japan [Published Professor Douglas Kell's blog - May 13 2013] To ensure that BBSRC Science remains at the frontier of international competitiveness, I arrange occasional visits abroad, approximately annually, to check this out on the ground (one such was the Big Data mission to the USA ). Given the strategic ...
Deals Of The Week Notes Bayer's Partnerships Ar... [Published The IN VIVO Blog - Feb 15 2013] Bayer Healthcare’s pharmaceuticals division has certainly had its ups and downs, and some ultra-tense relationships with partners—notably the very public lawsuit Onyx Pharmaceuticals filed against it, which the partners settled in October 2011. ...
Deals of the Week Ponders Eleventh-Hour Risk [Published The IN VIVO Blog - Jan 25 2013] Pharma dealmaking is usually fraught with all kinds of risks, whether technical, clinical, regulatory, financial, or otherwise. But Allergan’s buyout of migraine drug developer MAP Pharmaceuticals this week represented a unique roll of the dice: ...
NovAliX, Kyowa sign fragment-based drug discove... [Published PBR - News - Jan 15 2013] NovAliX has signed a fragment-based drug discovery alliance with Kyowa Hakko Kirin to develop new drug candidates targeting protein-protein interactions. ...
Alliance Deal of the Year Nominee: AZ/Amgen [Published The IN VIVO Blog - Dec 19 2012] It's time for the IN VIVO Blog's Fifth Annual Deal of the Year! competition. This year we're once again presenting awards in three categories to highlight the most interesting and creative deal making solutions of the year. The categories are: M&A ...